The therapeutic options previously analyzed, namely statins and ezetimibe, are dependent on LDL receptors, demonstrating limited efficacy in patients with homozygous FH variants, who do not reach the LDL-C levels recommended by the guidelines [103,104,105,106]. The gene discussed is LDLR; the disease is familial hyperaldosteronism.